Maze Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$32.98

−1.20%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $33.38
Volume: 9
Day's high: —
Day's low: —

In brief

Maze Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $1.83B.
Its shares closed at $33.38 on 4 Nov 2026, up 3.0% over the past year.
From India you can buy MAZE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Maze Therapeutics, Inc. (MAZE) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole MAZE share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade MAZE options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +26.3% (SPY −1.6%, XLV +13.5%). 3 months: +20.0% (SPY −0.4%, XLV +15.5%). 1 year: +3.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MAZE, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $33.38 was 20.8% above its 50-day average ($27.62) and 5.3% above its 200-day average ($31.71). It has closed above the 200-day for 2 sessions, since 3 Nov 2026. The 50-day average crossed below the 200-day on 19 May 2026, 117 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
10.1 days to cover short interest
7.5M shares were sold short at the 15 Oct 2026 settlement; covering them would take 10.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
36% of the way up its 52-week range
Closed at $33.38 on 4 Nov 2026: 37.8% below the 52-week high of $53.65 (16 Mar 2026) and 52.1% above the low of $21.95 (21 Sep 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+26.3%

6 months+26.1%

1 year+3.0%

5 years—

Newswire

About

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Website

Notable moves

September 22, 2026
+26.75%
March 25, 2026
−35.24%
September 11, 2025
+54.81%

Newswire

About

Website

Notable moves

September 22, 2026
+26.75%
March 25, 2026
−35.24%
September 11, 2025
+54.81%

Maze Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$32.98

−1.20%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $33.38
Volume: 9
Day's high: —
Day's low: —

In brief

Maze Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $1.83B.
Its shares closed at $33.38 on 4 Nov 2026, up 3.0% over the past year.
From India you can buy MAZE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Maze Therapeutics, Inc. (MAZE) shares from India?

Do I need the price of a whole MAZE share to invest?

How much can I invest in US stocks in a year?

Can I trade MAZE options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +26.3% (SPY −1.6%, XLV +13.5%). 3 months: +20.0% (SPY −0.4%, XLV +15.5%). 1 year: +3.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MAZE, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $33.38 was 20.8% above its 50-day average ($27.62) and 5.3% above its 200-day average ($31.71). It has closed above the 200-day for 2 sessions, since 3 Nov 2026. The 50-day average crossed below the 200-day on 19 May 2026, 117 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
10.1 days to cover short interest
7.5M shares were sold short at the 15 Oct 2026 settlement; covering them would take 10.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
36% of the way up its 52-week range
Closed at $33.38 on 4 Nov 2026: 37.8% below the 52-week high of $53.65 (16 Mar 2026) and 52.1% above the low of $21.95 (21 Sep 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+26.3%

6 months+26.1%

1 year+3.0%

5 years—

Newswire

About

Website

Notable moves

September 22, 2026
+26.75%
March 25, 2026
−35.24%
September 11, 2025
+54.81%

Newswire

About

Website

Notable moves

September 22, 2026
+26.75%
March 25, 2026
−35.24%
September 11, 2025
+54.81%

Maze Therapeutics, Inc.

Maze Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

10.1 days to cover short interest

36% of the way up its 52-week range

Maze Therapeutics, Inc.

Maze Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

10.1 days to cover short interest

36% of the way up its 52-week range